Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab + Rituximab/Venetoclax in Refractory or Relapsed CLL
2024-511474-68-00Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belimumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University Hospital Tübingen. Primary endpoint: Negativity rate of minimal residual disease in peripheral blood at end of induction. Started Jul 2024; status: completed.
02
Drugs
belimumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-511474-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511474-68-00.